Susanna High

Susanna High

Chief Operating OfficeratDyne Therapeutics· In proxies 2022–2023

Pay in FY2023+28% from the year before · Dyne Therapeutics stock +14.8% the same year

Susanna High was paid $2.0M in FY2023 (Dec), up 28%. Dyne Therapeutics stock rose 14.8% that year.

Pay$100 in the stock at the end of FY21 → $112
Pay is from the Summary Compensation Table of each Dyne Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Dyne TherapeuticsPublic company · 4 yr
    • Chief Operating Officer2022 – Present · 4 yrStock in role +34%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?